Lakewood-Amedex Biotherapeutics Announces Resistance Data For Nu-3 In Alignment With Presidential Advisory Council On Combating Antibiotic Resistant Bacteria
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high
A medicine company showed that their new treatment Nu-3 can stop bacteria from becoming resistant to drugs—which is a big problem doctors worry about. This is early-stage research, so watching whether the medicine actually works in real patients will tell you if the company is on the right track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.